Title:
ゲムシタビン及びEGFRインヒビターによる治療
Document Type and Number:
Japanese Patent JP2008501652
Kind Code:
A
Abstract:
The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and gemcitabine combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva(TM)).
Inventors:
Higgins, Brian
Kolinsky, Kenneth
Kolinsky, Kenneth
Application Number:
JP2007513817A
Publication Date:
January 24, 2008
Filing Date:
May 27, 2005
Export Citation:
Assignee:
F. HOFFMANN-LA ROCHE AKTIENGESELLSCHAFT
International Classes:
A61K31/7068; A61K31/4706; A61K31/498; A61K31/513; A61K31/517; A61K31/519; A61K31/5377; A61K31/7072; A61K45/00; A61P35/00; A61P35/04; A61P43/00
Domestic Patent References:
| JP2006503866A | 2006-02-02 | |||
| JP2003523949A | 2003-08-12 |
Attorney, Agent or Firm:
Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Shintaro Koike
Takashi Ishida
Fukumoto product
Tetsuji Koga
Shintaro Koike